Google Chrome
Safari
Firefox
Edge
Press Release / Mar 17, 2021
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Search
Approach to Product Development
Hovione’s assets represent value for life cycle management strategies, drugs repurposed route of administrations and paragraph IV opportunities in technically difficult generics.
Press Release / May 25, 2017
Hovione Announces Start of Phase 1 Clinical Trial of HY02
HY02, a Proprietary Minocycline Sterile Ointment to Treat a Subset of Anterior Ocular Inflammation
Press Release / Nov 27, 2014
Hovione files its first Investigational New Drug Application with the FDA
Article / Jun 08, 2009
A Well-Integrated Sideline. Deal to supply an inhaler device to Daiichi Sankyo marks a big victory for Hovione
C&EN, 8 June, 2009
Press Release / Dec 04, 2017
Hovione Announces Enrollment of First Patient in MARS
A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Press Release / Sep 20, 2019
Hovione announces successful end-of-phase 2 meeting with the FDA and outlines phase 3 program for minocycline topical gel
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Inhalation devices
Hovione’s inhalers offer our business partners access to simple, multipurpose, easy to use, globally competitive alternatives for inhalation delivery devices.